OverviewSuggest Edit
Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
| Type | Public | |
| Founded | 2012 | |
| HQ | Redwood City, CA, US | Map |
| Website | allakos.com |
Recent NewsAll News
- Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
- New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms
- Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
- Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Key People/Management at Allakos
Dan Janney
Chairman
Robert Alexander
Chief Executive Officer, Director
Robert Andreatta
Director
Mark Asbury
Chief Legal Officer, General Counsel
Paul Walker
Director
Craig Paterson
Chief Medical Officer
Allakos Office Locations
Allakos has an office in Redwood City
Redwood City, CA, US (HQ)
975 Island Dr #201
Allakos Financials and Metrics
Allakos Revenue
| USD | |
|---|---|
Net income (Q1, 2021) | (55.6m) |
EBIT (Q1, 2021) | (55.6m) |
Market capitalization (29-Jul-2021) | 4.4b |
Closing stock price (29-Jul-2021) | 81.5 |
Cash (31-Mar-2021) | 170.0m |
EV | 4.2b |
Allakos's current market capitalization is $4.4 b.
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|
General and administrative expense | 2.4m | 3.3m | 5.8m | 5.9m | 7.5m | 11.6m | 12.1m | 16.7m |
R&D expense | 7.1m | 8.7m | 15.1m | 14.1m | 16.1m | 18.3m | 28.3m | 38.9m |
Operating expense total | 9.5m | 12.0m | 20.9m | 20.1m | 23.6m | 29.9m | 40.4m | 55.6m |
EBIT | (9.5m) | (12.0m) | (20.9m) | (20.1m) | (23.6m) | (29.9m) | (40.4m) | (55.6m) |
Annual
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|
Net Income | (17.9m) | (29.0m) | (20.0m) | (39.0m) | (60.8m) | (27.8m) | (67.1m) | (55.6m) |
Depreciation and Amortization | 119.0k | 183.0k | 357.0k | 732.0k | 393.0k | 372.0k | ||
Accounts Payable | (647.0k) | 915.0k | 1.3m | 874.0k | 1.7m | 3.1m | 3.7m | (6.8m) |
Cash From Operating Activities | (17.4m) | (25.8m) | (13.3m) | (27.7m) | (43.9m) | (18.6m) | (43.7m) | (46.3m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | -0.4 x |
Allakos Cybersecurity Score
Allakos Environment, Social & Governance (ESG) Ratings
Allakos Online and Social Media Presence
Allakos's Trends
Allakos News and Updates
June 07, 2021
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO --
May 24, 2021
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) 45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwe…
March 30, 2021
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster pres…
March 01, 2021
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year ended …
October 26, 2020
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Management to host conference call and webcast today at 8:00 am ET --
August 10, 2020
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an …
Allakos Blogs
May 10, 2021
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
Content Import
Mon, 05/10/2021 - 16:02
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 at 4:01 PM EDT
This release is a backfill fr…
April 19, 2021
Allakos Appoints Baird Radford as Chief Financial Officer
Allakos Appoints Baird Radford as Chief Financial Officer
Content Import
Mon, 04/19/2021 - 16:02
Allakos Appoints Baird Radford as Chief Financial Officer
April 19, 2021 at 4:01 PM EDT
This release is a backfill from a News Wire
General
…
December 22, 2020
Allakos Appoints Natalie Holles to its Board of Directors
REDWOOD CITY, Calif. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles , president and chief executive officer of
November 09, 2020
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
Content Import
Mon, 11/09/2020 - 08:04
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
November 9, 2020 at 8:01 AM EST
This release is a backfil…
November 02, 2020
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
REDWOOD CITY, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020
October 29, 2020
Allakos Announces Pricing of Public Offering of Common Stock
Allakos Announces Pricing of Public Offering of Common Stock
Content Import
Wed, 10/28/2020 - 20:20
Allakos Announces Pricing of Public Offering of Common Stock
October 28, 2020 at 8:20 PM EDT
This release is a backfill from a News Wire
General
…
Allakos Frequently Asked Questions
When was Allakos founded?
Allakos was founded in 2012.
Who are Allakos key executives?
Allakos's key executives are Dan Janney, Robert Alexander and Robert Andreatta.
How many employees does Allakos have?
Allakos has 96 employees.
Who are Allakos competitors?
Competitors of Allakos include ALX Oncology, Vyriad and Sosei Heptares.
Where is Allakos headquarters?
Allakos headquarters is located at 975 Island Dr #201, Redwood City.
Where are Allakos offices?
Allakos has an office in Redwood City.
How many offices does Allakos have?
Allakos has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies